Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Pluristem Therapeutics Inc. (PSTI - Snapshot Report) recently reported a net loss of 38 cents in fiscal 2013 (ended Jun 30, 2013) wider than both the Zacks Consensus Estimate and the year-ago loss of 34 cents.

Revenues of $0.7 million in fiscal 2013 were down 5% from a year ago and short of the Zacks Consensus Estimate of $1 million.

The revenues were derived from the company’s agreement with United Therapeutics (UTHR - Analyst Report). The decline in revenues was due to the re-evaluation of the development period under the agreement with United Therapeutics.

Research and development expenses (net) increased 88% to $17.2 million, due to the increase in the company’s clinical trials expenses, salaries, full form materials expenses and consultants and subcontractor expenses. General and administrative expenses decreased by 14% to $5.6 million.

We note that Pluristem develops placenta-based cell therapies in collaboration with companies like United Therapeutics or through research and clinical institutions.

The cells from placenta are derived using the company's proprietary PluriX therapy. PLX-PAD, Pluristem's first candidate in development, is intended to treat peripheral artery disease (PAD).

Meanwhile, the United States Patent and Trademark Office granted Pluristem an important patent (U.S. Patent 8,529,888) for methods used in the treatment of PAD.

The patent is expected to expire in 2028. The company is also evaluating PLX-PAD for the treatment of Intermittent Claudication (IC) and Buerger's disease.

We remind investors that Pluristem received a major setback in Jun 2013 when the U.S. Food and Drug Administration placed a clinical hold on a phase II IC study following a serious allergic reaction in one of the patients who required subsequent hospitalization.

The news of clinical hold continues to loom large on Pluristem’s stock price.

Pluristem currently carries a Zacks Rank #3 (Hold). Right now, Actelion Ltd. (ALIOF) and Biogen Idec Inc. (BIIB - Analyst Report) looks well placed with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%